First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.

Trial Details

NCT ID
NCT07355205
Phase
PHASE1 / PHASE2
Sponsor
Washington University School of Medicine
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Ipilimumab
  • Nivolumab
  • Nogapendekin alfa inbakicept
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Histologically or cytologically confirmed, previously untreated or recurrent metastatic NSCLC.
  • Availability of archival biopsy tissue or willingness to undergo a biopsy prior to C1D1 for biomarker analysis, including PD-L1 by IHC using a CLIA…
  • Measurable disease per RECIST 1.1.
  • At least 18 years of age.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →